Cargando…

Feasibility and outcome of the Rotapro system in treating severely calcified coronary lesions: The Rotapro study

BACKGROUND: The Rotapro study was conducted to evaluate the safety and feasibility of the new Rotapro rotational atherectomy system (RAS) for lesion preparation in calcified coronary artery stenosis. METHODS: Between 2015 and 2019 consecutive patients undergoing rotational atherectomy (RA) with the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayoub, Mohamed, Tajti, Peter, Ferenc, Miroslaw, Akin, Ibrahim, Behnes, Michael, Neumann, Franz-Josef, Mashayekhi, Kambis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Via Medica 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508079/
https://www.ncbi.nlm.nih.gov/pubmed/34671968
http://dx.doi.org/10.5603/CJ.a2021.0128
_version_ 1785107453736648704
author Ayoub, Mohamed
Tajti, Peter
Ferenc, Miroslaw
Akin, Ibrahim
Behnes, Michael
Neumann, Franz-Josef
Mashayekhi, Kambis
author_facet Ayoub, Mohamed
Tajti, Peter
Ferenc, Miroslaw
Akin, Ibrahim
Behnes, Michael
Neumann, Franz-Josef
Mashayekhi, Kambis
author_sort Ayoub, Mohamed
collection PubMed
description BACKGROUND: The Rotapro study was conducted to evaluate the safety and feasibility of the new Rotapro rotational atherectomy system (RAS) for lesion preparation in calcified coronary artery stenosis. METHODS: Between 2015 and 2019 consecutive patients undergoing rotational atherectomy (RA) with the new Rotapro system and the conventional rotablator (Rotablator) were included from the Bad Krozingen Rotablation Registry. The primary endpoint was the incidence of in-hospital major adverse cardiovascular and cerebral event (MACCE) rate. RESULTS: Rotablation was performed in 3.6% of all patients (n = 597) treated by percutaneous coronary intervention. Procedural outcomes were compared according to the applied RAS (n = 246 Rotapro vs. n = 351 Rotablator). Overall technical success was achieved in 98.3% of patients. The primary endpoint of in-hospital MACCE was comparable between the Rotapro- and the Rotablator-group (3.7% vs. 5.7%, respectively, p = 0.254). The Rotapro group was associated with significant reductions of fluoroscopy time (30 vs. 38 min, p < 0.0001), procedural time (82.5 vs. 96 min, p = 0.0003), applied contrast volume (210 vs. 290 mL, p < 0.0001) and radiation dose (6129 vs. 9827 cGy*cm(2), p < 0.0001) compared to the Rotablator group. CONCLUSIONS: The present study demonstrates the safety and efficacy of the new Rotapro system. Inhospital MACCE rates were comparable between both RAS, whereas Rotapro was associated with less fluoroscopy time, radiation dose as well as contrast use.
format Online
Article
Text
id pubmed-10508079
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Via Medica
record_format MEDLINE/PubMed
spelling pubmed-105080792023-09-20 Feasibility and outcome of the Rotapro system in treating severely calcified coronary lesions: The Rotapro study Ayoub, Mohamed Tajti, Peter Ferenc, Miroslaw Akin, Ibrahim Behnes, Michael Neumann, Franz-Josef Mashayekhi, Kambis Cardiol J Interventional Cardiology BACKGROUND: The Rotapro study was conducted to evaluate the safety and feasibility of the new Rotapro rotational atherectomy system (RAS) for lesion preparation in calcified coronary artery stenosis. METHODS: Between 2015 and 2019 consecutive patients undergoing rotational atherectomy (RA) with the new Rotapro system and the conventional rotablator (Rotablator) were included from the Bad Krozingen Rotablation Registry. The primary endpoint was the incidence of in-hospital major adverse cardiovascular and cerebral event (MACCE) rate. RESULTS: Rotablation was performed in 3.6% of all patients (n = 597) treated by percutaneous coronary intervention. Procedural outcomes were compared according to the applied RAS (n = 246 Rotapro vs. n = 351 Rotablator). Overall technical success was achieved in 98.3% of patients. The primary endpoint of in-hospital MACCE was comparable between the Rotapro- and the Rotablator-group (3.7% vs. 5.7%, respectively, p = 0.254). The Rotapro group was associated with significant reductions of fluoroscopy time (30 vs. 38 min, p < 0.0001), procedural time (82.5 vs. 96 min, p = 0.0003), applied contrast volume (210 vs. 290 mL, p < 0.0001) and radiation dose (6129 vs. 9827 cGy*cm(2), p < 0.0001) compared to the Rotablator group. CONCLUSIONS: The present study demonstrates the safety and efficacy of the new Rotapro system. Inhospital MACCE rates were comparable between both RAS, whereas Rotapro was associated with less fluoroscopy time, radiation dose as well as contrast use. Via Medica 2023-08-31 /pmc/articles/PMC10508079/ /pubmed/34671968 http://dx.doi.org/10.5603/CJ.a2021.0128 Text en Copyright © 2023 Via Medica https://creativecommons.org/licenses/by-nc-nd/4.0/This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially
spellingShingle Interventional Cardiology
Ayoub, Mohamed
Tajti, Peter
Ferenc, Miroslaw
Akin, Ibrahim
Behnes, Michael
Neumann, Franz-Josef
Mashayekhi, Kambis
Feasibility and outcome of the Rotapro system in treating severely calcified coronary lesions: The Rotapro study
title Feasibility and outcome of the Rotapro system in treating severely calcified coronary lesions: The Rotapro study
title_full Feasibility and outcome of the Rotapro system in treating severely calcified coronary lesions: The Rotapro study
title_fullStr Feasibility and outcome of the Rotapro system in treating severely calcified coronary lesions: The Rotapro study
title_full_unstemmed Feasibility and outcome of the Rotapro system in treating severely calcified coronary lesions: The Rotapro study
title_short Feasibility and outcome of the Rotapro system in treating severely calcified coronary lesions: The Rotapro study
title_sort feasibility and outcome of the rotapro system in treating severely calcified coronary lesions: the rotapro study
topic Interventional Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508079/
https://www.ncbi.nlm.nih.gov/pubmed/34671968
http://dx.doi.org/10.5603/CJ.a2021.0128
work_keys_str_mv AT ayoubmohamed feasibilityandoutcomeoftherotaprosystemintreatingseverelycalcifiedcoronarylesionstherotaprostudy
AT tajtipeter feasibilityandoutcomeoftherotaprosystemintreatingseverelycalcifiedcoronarylesionstherotaprostudy
AT ferencmiroslaw feasibilityandoutcomeoftherotaprosystemintreatingseverelycalcifiedcoronarylesionstherotaprostudy
AT akinibrahim feasibilityandoutcomeoftherotaprosystemintreatingseverelycalcifiedcoronarylesionstherotaprostudy
AT behnesmichael feasibilityandoutcomeoftherotaprosystemintreatingseverelycalcifiedcoronarylesionstherotaprostudy
AT neumannfranzjosef feasibilityandoutcomeoftherotaprosystemintreatingseverelycalcifiedcoronarylesionstherotaprostudy
AT mashayekhikambis feasibilityandoutcomeoftherotaprosystemintreatingseverelycalcifiedcoronarylesionstherotaprostudy